Aardvark Therapeutics Inc
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Aardvark Therapeutics Inc
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
/ 
Others were interested in
See all stocksFrequently asked questions
To buy Aardvark Therapeutics Inc stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Aardvark Therapeutics Inc by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Aardvark Therapeutics Inc is AARD:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Aardvark Therapeutics Inc has its primary listing on NASDAQ. You can trade Aardvark Therapeutics Inc with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Aardvark Therapeutics Inc is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Aardvark Therapeutics Inc as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Aardvark Therapeutics Inc.